Is hydrophobia necessary for the hepatologist prescribing nonselective beta‐blockers in cirrhosis?
Marco Senzolo, Elena Nadal, Evangelos Cholongitas, Andrew K. Burroughs – 10 January 2011
Insulin sensitizers in nonalcoholic steatohepatitis
Stephen A. Harrison, Steven Schenker, Kenneth Cusi – 10 January 2011
Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis–associated liver disease
Peter Witters, Louis Libbrecht, Tania Roskams, Kris De Boeck, Lieven Dupont, Marijke Proesmans, François Vermeulen, Birgitta Strandvik, Anders Lindblad, Xavier Stéphenne, Etienne Sokal, Serge Gosseye, Sam Heye, Geert Maleux, Raymond Aerts, Diethard Monbaliu, Jacques Pirenne, Ilse Hoffman, Frederik Nevens, David Cassiman – 10 January 2011
Outcomes in children who underwent transplantation for autoimmune hepatitis
Steven R. Martin, Fernando Alvarez, Ravinder Anand, Changhong Song, Wanrong Yin – 6 January 2011 – The outcomes of 113 children with autoimmune hepatitis (AIH), registered with Studies of Pediatric Liver Transplantation and who underwent transplantation between 1995 and 2006, were compared with those who underwent transplantation for other diagnoses (non‐AIH). A total of 4.9% of liver transplants were for AIH; 81% of these patients had AIH type 1 and most underwent transplantation for complications of chronic disease (60%), the majority in females (72%).
The GRACILE mutation introduced into Bcs1l causes postnatal complex III deficiency: A viable mouse model for mitochondrial hepatopathy
Per Levéen, Heike Kotarsky, Matthias Mörgelin, Riitta Karikoski, Eskil Elmér, Vineta Fellman – 28 December 2010 – Mitochondrial dysfunction is an important cause for neonatal liver disease. Disruption of genes encoding oxidative phosphorylation (OXPHOS) components usually causes embryonic lethality, and thus few disease models are available. We developed a mouse model for GRACILE syndrome, a neonatal mitochondrial disease with liver and kidney involvement, caused by a homozygous BCS1L mutation (232A>G).
Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen–positive patients
Teerha Piratvisuth, Patrick Marcellin – 22 December 2010
Molecular therapy for obesity and diabetes based on a long‐term increase in hepatic fatty‐acid oxidation
Josep M. Orellana‐Gavaldà, Laura Herrero, Maria Ida Malandrino, Astrid Pañeda, Maria Sol Rodríguez‐Peña, Harald Petry, Guillermina Asins, Sander Van Deventer, Fausto G. Hegardt, Dolors Serra – 22 December 2010 – Obesity‐induced insulin resistance is associated with both ectopic lipid deposition and chronic, low‐grade adipose tissue inflammation. Despite their excess fat, obese individuals show lower fatty‐acid oxidation (FAO) rates. This has raised the question of whether burning off the excess fat could improve the obese metabolic phenotype.
Two solutions in search of a problem
John S. White, John P. Foreyt – 22 December 2010
Effects of beta‐blockers on survival for patients with cirrhosis and refractory ascites
Gin‐Ho Lo – 22 December 2010
Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis
Andrew D. Yeoman, Rachel H. Westbrook, Yoh Zen, Paola Maninchedda, Bernard C. Portmann, John Devlin, John G. O'Grady, Phillip M. Harrison, Michael A. Heneghan – 22 December 2010 – Autoimmune hepatitis (AIH) typically responds to treatment in 90% of patients. Early prediction of treatment outcome would be advantageous in clinical practice. We evaluated whether parameters at initiation of therapy or changes in these parameters at day 3 and day 7 following corticosteroid initiation predicted treatment failure.